SUBSCRIBERS
China cancer patients turn to unapproved drugs on grey market
Published Mon, Dec 26, 2016 · 09:50 PM
Shanghai
WHEN her father's lung cancer worsened, Yin Min, a 51-year-old financial broker from Shanghai, faced a choice: pay nearly US$3,000 a month for an approved drug or pay a fraction of the price for a generic drug not approved for use in China.
Ms Yin, like many families in China, turned to the increasingly popular, unregulated market of online pharmacies, agents and peer groups for drugs.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue